Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-Authorization, Multicenter, Longitudinal, Observational Safety Registry Study for Patients Treated With Voretigene Neparvovec in US

NCT03597399 is registered in ClinicalTrials.gov with Spark Therapeutics, Inc. as lead sponsor.

NCT NCT03597399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03597399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-Authorization, Multicenter, Longitudinal, Observational Safety Registry Study for Patients Treated With Voretigene Neparvovec in US
Lead sponsor
Spark Therapeutics, Inc.
Phase
Observational
Overall status
Completed
Start date
January 10, 2019
Completion date
June 30, 2025
Enrollment
87 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

confirmed biallelic rpe65 mutation-associated retinal dystrophy